TIDMUPR
RNS Number : 3154O
Uniphar PLC
31 January 2023
Uniphar plc
Full Year Trading Update and Notice of Results
Dublin, London | 31 January 2023: Uniphar plc (the "Group" or
"Uniphar"), an international diversified healthcare services
business servicing the requirements of more than 200 multinational
pharmaceutical and medical technology manufacturers, today
announces the following unaudited trading update for the year ended
31 December 2022.
The business performed in line with the Group's expectations for
2022 at both a gross profit and EBITDA level, while delivering
normalised free cashflow conversion above our medium-term guidance.
This represents a strong performance in the period, leveraging the
Group's scale, leading market positions and diverse platforms to
mitigate continued macro-economic uncertainty and inflationary
pressure, demonstrating the continued resilience and potential of
the business.
The Group achieved organic gross profit growth in excess of 5%,
driven by organic growth across each division and an outperformance
in Supply Chain & Retail.
During the period, Uniphar continued to deliver on its strategic
objectives by meeting the needs of healthcare manufacturers through
the provision of higher value services.
The Group continues to maintain a strong liquidity position,
with lower than projected net debt at year-end.
Outlook
In 2023, Uniphar is well positioned to deliver organic gross
profit growth across all divisions, with the additional benefit of
the full year impact of acquisitions announced in 2022. The Group's
medium-term organic gross profit growth targets at a divisional
level are unchanged.
M&A will continue to play an important role in Uniphar's
growth strategy, and the Group continues to have a disciplined
approach to capital allocation while managing an active pipeline of
acquisition opportunities to further enhance the Group's growth
potential.
Commercial & Clinical
The Group remains focused on its strategy of building a
pan-European presence and continued to leverage existing
relationships into new geographies during the period. We completed
the acquisition of Inspired Health, a US-based healthcare insights
and intelligence consultancy, in October 2022. The integration of
BESTMSLs, CoRRect Medical and E4H, acquired in 2021, continue to
progress in line with expectations. The Group is targeting
mid-single digit organic growth in gross profit in this division in
FY 2023.
Product Access
The Group's strategy for Product Access is to become a global
leader in the ethical provision of access to medicines which remain
unlicensed at the point of care and the provision of Expanded
Access Programs to innovative new medicines. The acquisition of
BModesto, which completed in November 2022, is a strong addition to
the Group's capabilities in the strategically important continental
European market. Orspec, acquired in August 2022, represents our
first entry into the strategically important APAC region. These
follow the acquisition of Devonshire Healthcare Services Limited in
December 2021, expanding the Group's access into key hospitals in
the Middle East and North Africa (" MENA"). The Group is targeting
a return to double digit organic growth in gross profit in this
division in the second half of 2023.
Supply Chain & Retail
The Group's market leadership position in Ireland is re-enforced
by a growing symbol group offering for retail pharmacies. This
division has performed strongly during the period and once again
outperformed its medium term organic gross profit growth guidance
demonstrating the benefits of the growing scale of our platform.
The acquisition of McCauley's Pharmacy Group, originally announced
in September 2022, was cleared by the Competition and Consumer
Protection Commission (CCPC) on 20(th) January 2023, subject to a
number of legally binding commitments. We expect the transaction to
close imminently. The Group is targeting low single digit organic
growth in gross profit in this division in FY 2023.
Ger Rabbette, Uniphar Group Chief Executive Officer said:
"Today's trading update reflects a strong performance by the
Group in 2022, with organic gross profit growth in excess of 5%.
Our teams and our people have once again performed exceptionally
well, delivering for our customers in what has been another
uncertain and, at times, challenging period.
We have continued to invest in our diversified service offering
both organically and through M&A, announcing four acquisitions
during the period.
In Commercial & Clinical we acquired Inspired Health, a
strongly innovative market research company, adding another vital
component to our high value commercialisation offering and further
increasing our scale in the world's largest healthcare market.
In Product Access, the acquisition of BModesto and Orspec
expands our reach in continental Europe and the APAC region and
further accelerates our growth towards market leadership in the
provision of Unlicensed Medicines and the delivery of Expanded
Access Programs globally.
In Supply Chain & Retail, the acquisition of McCauley
further improves our leading position in the Irish retail pharmacy
market.
We are confident and remain on track to achieve our strategic
objective of doubling EBITDA within 5 years of IPO."
Notice of Results
The Group expects to publish its final results for the year
ended 31 December 2022 at 07:00 am (GMT) on 28(th) February
2023.
A conference call for analysts and investors will be held at
9.00 am (GMT) on 28(th) February 2023 to discuss the Group's final
results. Analysts and investors who wish to participate should
visit www.uniphar.ie to register.
The Company's final results press release and presentation will
also be available on the website at 07.00 am (GMT) on 28(th)
February 2023 at www.uniphar.ie .
For further details contact:
Uniphar +353 (0) 1 428 7777
Allan Smylie
------------------------------
Head of Strategy and IR investor.relations@uniphar.ie
------------------------------
Davy (Joint Corporate Broker, Nominated
Adviser and Euronext Growth Listing
Sponsor) +353 (0) 1 679 6363
------------------------------
Barry Murphy
------------------------------
Niall Gilchrist
------------------------------
Lauren O'Sullivan
------------------------------
RBC Capital Markets (Joint Corporate
Broker) +44 (0) 20 7653 4000
------------------------------
Jonathan Hardy
------------------------------
Jamil Miah
------------------------------
Stifel Nicolaus Europe Limited (Joint
Corporate Broker) +44 (0) 20 7710 7600
------------------------------
Matt Blawat
------------------------------
Ben Maddison
------------------------------
Francis North
------------------------------
Q4 PR +353 (0) 1 475 1444
or
------------------------------
(Public Relations Adviser to Uniphar) +353 87 235 6461
------------------------------
Iarla Mongey
------------------------------
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an
international diversified healthcare services business servicing
the requirements of more than 200 multinational pharmaceutical and
medical technology manufacturers across three divisions -
Commercial & Clinical, Product Access and Supply Chain &
Retail. The Group is active in Ireland, the UK, Europe, the US and
Australia.
The Company's vision is to improve patient access to
pharmaco-medical products and treatments by enhancing connectivity
between manufacturers and healthcare stakeholders. Uniphar
represents a strong combination of scale, growth, and
profitability.
Commercial & Clinical
In Commercial & Clinical, the Group provides outsourced
sales, marketing & distribution solutions to multinational
pharmaceutical and medical device manufacturers. Active in Ireland,
the UK, Benelux, the Nordics, Germany and the US, the Group is
growing with its clients to provide pan-European solutions, with a
targeted service offering in the US. Uniphar has built fully
integrated digitally enabled customer centric solutions that are
supported by our highly experienced and clinically trained teams,
leveraging our digital technology and insights which allows us to
deliver consistently exceptional outcomes for our clients.
Product Access
In Product Access, the Group is growing two distinct service
offerings: 1) "On Demand", which are pharmacy led solutions for
sourcing and supplying unlicensed medicines to meet the needs of
both retail and hospital pharmacists; and 2) "Exclusive Access",
which are manufacturer led solutions for controlling the release of
speciality medicines for specifically approved patient populations
in agreed markets. The Group currently delivers product access
solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with c. 53%
market share in the wholesale/hospital market, supported by a
network of 386 owned, franchised and symbol group pharmacies. The
business supports the diverse customer base through the provision
of strong service levels coupled with innovative commercial
initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and
infrastructure are also utilised for the benefit of the Commercial
& Clinical and Product Access divisions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTZZGFMNGNGFZM
(END) Dow Jones Newswires
January 31, 2023 02:00 ET (07:00 GMT)
Uniphar (LSE:UPR)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Uniphar (LSE:UPR)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
